Country
Switzerland
A candidate antibiotic designed to treat patients with serious infections passed the first of two Phase 3 hurdles after patients with acute bacterial skin and skin structure infections responded to treatment.
Full text available to subscribers only. Click here for information on subscribing to MedNous.